Current treatment of non-alcoholic fatty liver disease
Current treatment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in Western World and frequently associated with insulin resistance and overweight and occurs often with type 2 diabetes. Interestingly, NAFLD is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease (CVD). Significantly, NAFLD is associated with an increased risk of all-cause mortality and predicts future CVD events independent of age, sex, LDL-cholesterol and features of metabolic syndrome. Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as metformin and statins do not cause harm and the thiazolidinediones (TZDs) may even confer a therapeutic benefit in NAFLD. Interestingly, medical and surgical treatments of obesity show potential benefit in treating NAFLD. In this review, we have focused on the safety and therapeutic impact of TZDs, statins, metformins and obesity medications in NAFLD. The potential benefit of bariatric surgery and the role of weight loss per se in treating NAFLD are also discussed.
bariatric surgery, insulin resistance, lifestyle, non-alcoholic fatty liver disease, obesity, treatment
188-195
Ahmed, Mohamed H.
ed037a05-9770-4c1f-80a8-bd79fc83ee35
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
28 June 2008
Ahmed, Mohamed H.
ed037a05-9770-4c1f-80a8-bd79fc83ee35
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Ahmed, Mohamed H. and Byrne, Christopher D.
(2008)
Current treatment of non-alcoholic fatty liver disease.
Diabetes, Obesity and Metabolism, 11 (3), .
(doi:10.1111/j.1463-1326.2008.00926.x).
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in Western World and frequently associated with insulin resistance and overweight and occurs often with type 2 diabetes. Interestingly, NAFLD is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease (CVD). Significantly, NAFLD is associated with an increased risk of all-cause mortality and predicts future CVD events independent of age, sex, LDL-cholesterol and features of metabolic syndrome. Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as metformin and statins do not cause harm and the thiazolidinediones (TZDs) may even confer a therapeutic benefit in NAFLD. Interestingly, medical and surgical treatments of obesity show potential benefit in treating NAFLD. In this review, we have focused on the safety and therapeutic impact of TZDs, statins, metformins and obesity medications in NAFLD. The potential benefit of bariatric surgery and the role of weight loss per se in treating NAFLD are also discussed.
Text
DOM._NAFLD._PMID_18564173.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: 28 June 2008
Keywords:
bariatric surgery, insulin resistance, lifestyle, non-alcoholic fatty liver disease, obesity, treatment
Identifiers
Local EPrints ID: 60863
URI: http://eprints.soton.ac.uk/id/eprint/60863
ISSN: 1462-8902
PURE UUID: 3afadd2d-88ba-4cbd-adac-cf2437415ba0
Catalogue record
Date deposited: 23 Sep 2008
Last modified: 16 Mar 2024 03:07
Export record
Altmetrics
Contributors
Author:
Mohamed H. Ahmed
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
